The FDA on January 16, 2025, approved LUMAKRAS® with VECTIBIX® for adult patients with KRAS G12C-mutated metastatic Colorectal Cancer (mCRC), as determined by an FDA-approved test, who have received prior Fluoropyrimidine, Oxaliplatin, and Irinotecan-based chemotherapy. LUMAKRAS® and VECTIBIX® are products of Amgen Inc.
Bottom Ad
Advertisement
Subscribe
